Sir, We read with great interest the report of a Tunisian family by Rouzier et al. (2011) describing the neurological disorder linked to a novel heterozygous missense mutation in MFN2 (1p36.2) (Rouzier et al., 2011) . MFN2 mutations typically cause autosomal dominant axonal Charcot-Marie-Tooth disease (CMT2A, OMIM 609260), with peripheral nerve degeneration occasionally associated with visual failure and optic atrophy (Zuchner et al., 2004 (Zuchner et al., , 2006 . Interestingly, the clinical manifestations among mutational carriers in this Tunisian family were even more variable, ranging from asymptomatic subclinical disease to an axonal sensorimotor neuropathy complicated by optic atrophy, deafness, cerebellar ataxia and proximal myopathy. Furthermore, the intriguing finding of cytochrome c oxidase (COX)-deficient fibres and multiple mitochondrial DNA deletions in skeletal muscle biopsies suggest that MFN2 mutations can result in disturbed mitochondrial DNA maintenance and an overt respiratory chain defect, in addition to marked fragmentation of the mitochondrial network. These deleterious consequences are strikingly reminiscent of the pathological features recently highlighted in Brain for autosomal dominant optic atrophy due to OPA1 mutations Hudson et al., 2008; Yu-Wai-Man et al., 2010a) . Here, we provide additional evidence that MFN2-associated neuropathy is a novel disorder of mitochondrial DNA maintenance in a study of 58 probands with CMT2A and confirmed MFN2 mutations (Table 1) , compared with 131 age-matched normal controls.
Total genomic DNA was extracted from the leucocyte fraction of venous blood samples. The average cellular mitochondrial DNA content was quantified with a SYBR Green TM quantitative polymerase chain reaction assay on a MyiQ TM real-time polymerase chain reaction detection system (Biorad), with MTND1 as the mitochondrial template and GAPDH as the nuclear-encoded housekeeping template (Yu-Wai-Man et al., 2010a) . Relative mitochondrial DNA copy number was derived from the difference in threshold cycle (C t ) values obtained for MTND1 and GAPDH using the 2ð2 ÀÁ t CÞ equation to account for two copies of GAPDH per cell nucleus.
Mitochondrial DNA levels in the MFN2 group [mean mitochondrial DNA copy number = 195.7, standard deviation (SD) = 126.6, n = 58] were significantly higher compared with controls (mean mitochondrial DNA copy number = 60.9, SD = 42.3, n = 131, doi:10.1093/brain/aws049
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Advance Access publication April 4, 2012 ß The Author (2012). Published by Oxford University Press on behalf of the Guarantors of Brain. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. P 5 0.0001) (Fig. 1A) . Given the suggestion by Rouzier et al. (2011) that MFN2 mutations involving the functional GTPase domain were more likely to precipitate the severe multi-system phenotype documented in their family, we performed a subgroup analysis based on whether or not patients in our cohort harboured mutations within the highly conserved GTPase gene region. No significant difference was found between these two distinct mutational subgroups (P = 0.5957) (Fig. 1B) .
Although we have previously shown that variation in the differential blood cell count can affect blood-derived mitochondrial DNA copy number (Pyle et al., 2010) , the 3-fold increase in mitochondrial DNA content detected in our MFN2 cohort was substantially greater than the error attributable to this possible confounding factor. Mitochondrial proliferation is a wellrecognized important diagnostic feature in skeletal muscle of patients with a range of mitochondrial cytopathies (Taylor et al., 2004; Aure et al., 2006) . This compensatory mechanism is thought to occur in response to an underlying cellular bioenergetic crisis (the 'sick mitochondrion hypothesis'), which leads to the classical 'ragged-red fibre' appearance on Gomori Trichrome or succinate dehydrogenase staining (Chinnery and Samuels, 1999; Capps et al., 2003; Durham et al., 2007) . In this study, we have demonstrated the same phenomenon in blood leucocytes derived from patients with MFN2 mutations. Although Rouzier et al. (2011) determined mitochondrial DNA copy number in four skeletal muscle biopsies, they only report on the absence of mitochondrial DNA depletion in homogenate muscle extracts (Table 1) . Pathologically increased mitochondrial DNA levels have been detected in laser-microdissected single skeletal muscle fibres from patients with OPA1 mutations, this effect being particularly marked in COX-deficient muscle fibres (YuWai-Man et al., 2010b). Given the overlapping clinical, histological and molecular characteristics observed in these two primary disorders of mitochondrial dynamics, it would be of great interest to know whether mitochondrial DNA proliferation was also present in muscle fibres from patients with MFN2 mutations, especially in the two biopsies noted to have ragged-red fibres.
MFN2 is the newest member of an expanding group of nuclear mitochondrial disorders characterized by disturbed mitochondrial DNA maintenance, a process which, increasingly, seems to be intrinsically related to the state of the mitochondrial network (Chen et al., 2010; Elachouri et al., 2011) . Our observation that MFN2 mutations cause mitochondrial proliferation in blood adds weight to the novel disease mechanism reported by Rouzier et al. (2011) . Future work is needed to disentangle the complex interplay between disturbed mitochondrial fusion and fission, mitochondrial DNA instability and the eventual development of both neurological and visual deficits in patients with CMT2A and MFN2 mutations. Letter to the Editor Brain 2012: 135; 1-3 | e219
